Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 2
Submit an article Journal homepage
119
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors

Laetitia LargeaudLaboratoire D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; ;Université Toulouse III Paul Sabatier, Toulouse, France; ;UMR1037-INSERM, ERL5294 CNRS, Cancer Research Center of Toulouse, Toulouse, France; View further author information
,
Sarah BertoliUniversité Toulouse III Paul Sabatier, Toulouse, France; ;UMR1037-INSERM, ERL5294 CNRS, Cancer Research Center of Toulouse, Toulouse, France; ;Service D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; View further author information
,
Emilie BérardService D'Epidémiologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; ;UMR 1027, INSERM-Université de Toulouse III, Toulouse, France; View further author information
,
Stéphanie DufrechouLaboratoire D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; View further author information
,
Naïs PradeLaboratoire D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; View further author information
,
Noémie GadaudService D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; View further author information
,
Suzanne TavitianService D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; View further author information
,
Pierre BoriesRéseau Onco-Occitanie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, FranceView further author information
,
Isabelle LuquetLaboratoire D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; View further author information
,
Audrey SarryService D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; View further author information
,
Véronique De MasLaboratoire D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; ;Université Toulouse III Paul Sabatier, Toulouse, France; ;UMR1037-INSERM, ERL5294 CNRS, Cancer Research Center of Toulouse, Toulouse, France; View further author information
,
Françoise HuguetService D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; View further author information
,
Eric DelabesseLaboratoire D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; ;Université Toulouse III Paul Sabatier, Toulouse, France; ;UMR1037-INSERM, ERL5294 CNRS, Cancer Research Center of Toulouse, Toulouse, France; View further author information
&
Christian RécherUniversité Toulouse III Paul Sabatier, Toulouse, France; ;UMR1037-INSERM, ERL5294 CNRS, Cancer Research Center of Toulouse, Toulouse, France; ;Service D'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; Correspondence[email protected]
View further author information
 show all
Pages 473-476 | Received 08 Feb 2019, Accepted 10 Sep 2019, Published online: 30 Sep 2019

References

  • Bullinger L, Dohner K, Dohner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35(9):934–946.
  • Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089.
  • Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. JCO. 2010;28(22):3636–3643.
  • Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116(12):2122–2126.
  • DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
  • Megias-Vericat JE, Martinez-Cuadron D, Sanz MA, et al. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann Hematol. 2018;97:1115–1153.
  • Bertoli S, Tavitian S, Berard E, et al. Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies. Leukemia Lymphoma. 2019;60(1):238–241.
  • Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16(9):1025–1036.
  • Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. JCO. 2012;30(20):2492–2499.
  • Hills RK, Gale R, Linch DC, et al. Outcomes of Relapsed/Refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials. Blood. 2018;132:664.
  • Bertoli S, Tavitian S, Huynh A, et al. Improved outcome for AML patients over the years 2000-2014. Blood Cancer J. 2017;7(12):635.
  • Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.
  • Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.